pyrroles has been researched along with Biliary Tract Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barry, C; Betancourt, O; Blot, V; Coronella, J; D'Hooge, F; Fujita, R; Galvan, D; Gymnopoulos, M; Hartley, JA; Howard, PW; Lieuw, V; Newman, R; Nguyen, S; Pardo, R; Patel, N; Snedden, J; Stewart, C; Vijayakrishnan, B; Villicana, J; Wojciak, J; Wong, E | 1 |
| Choi, MK; Hong, JY; Jung, HA; Kang, WK; Lee, J; Lim, HY; Maeng, CH; Park, JO; Park, SH; Park, YS; Yi, JH | 1 |
| Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S | 1 |
3 other study(ies) available for pyrroles and Biliary Tract Cancer
| Article | Year |
|---|---|
TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors.
Topics: Animals; Antineoplastic Agents; Benzodiazepines; Biliary Tract Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunoconjugates; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oncogenes; Proto-Oncogene Proteins c-met; Pyrroles; Rats; Rats, Sprague-Dawley; Stomach Neoplasms; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2020 |
Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Disease-Free Survival; Female; Genetic Association Studies; Homozygote; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrroles; Stomach Neoplasms; Sunitinib; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Proto-Oncogene Proteins c-akt; Pteridines; Pyrimidines; Pyrroles; Receptor, IGF Type 1 | 2010 |